Clinical trials: Polymorphism
Varicose Veins, MTHFR
Prevalence of MTHFR Polymorphisms in Venous Disease
The etiologies of varicose veins and the progression to more serious forms of chronic venous disease and identification of appropriate diagnostic tests to better aid patient management by identifying individuals who may benefit…
- Conditions
- Varicose Veins, MTHFR, Venous Disease, Thrombosis
- Trial name
- MTHFR (NCT01993914)
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Health Diagnostic Laboratory, Inc.
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)
Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.
- Trial name
- NCT02591862
- Testing
- Coversin
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- AKARI Therapeutics
Schizophrenia
A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients
This study is a 12-week, double-blind, placebo-controlled trial of L-methylfolate 15 mg/d supplementation in schizophrenia patients with mild or greater negative symptoms.
- Trial name
- NCT01091506
- Testing
- L-methylfolate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Pamlab, Inc.
ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
Explore the relationship between drug target ALK gene single nucleotide polymorphisms and ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets'…
- Trial name
- Drugs-SNPs (NCT05987956)
- Testing
- ALECENSA - alectinib hydrochloride capsule
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Medicine Invention Design, Inc
Helicobacter Pylori Infection
A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
This study compared efficacy and safety of basic triple therapy according to treatment period. This study evaluated Effect of CYP2C19 genetic polymorphisms on the efficacy
- Trial name
- NCT03099876
- Testing
- treatment period
- Where
- 4 sites in South Korea
- Volunteers
- 320 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Catecholaminergic Polymorphic Ventricular Tachycardia Type 1
Treatment of an Inherited Ventricular Arrhythmia
The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the treatment of Catecholaminergic Polymorphic Ventricular…
- Trial name
- NCT05122975
- Testing
- S48168 (ARM210)
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 8 people
- Sponsor
- RyCarma Therapeutics, Inc.
Huntington Disease
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their…
- Trial name
- NCT06667414
- Where
- 45 sites in United States, Argentina and 10 more
- Volunteers
- 574 people
- Sponsor
- Hoffmann-La Roche
Hypercholesterolemia, Myopathy
DNA Diagnostic System for Statin Safety and Efficacy
Lipitor®, Zocor®, and Crestor® are statin drugs commonly taken to lower cholesterol and prevent heart disease. Statins lower cholesterol by different amounts in different patients and sometimes statins cause muscle pain, cramps…
- Trial name
- SIM (NCT00767130)
- Where
- 3 sites in United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Genomas, Inc
Small Cell Lung Cancer
Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Explore the relationship between drug target topoisomerase II gene single nucleotide polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug…
- Trial name
- Drugs-SNPs (NCT01064466)
- Testing
- ETOPOSIDE - Usual, ETOPOSIDE - Study
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Catecholaminergic Polymorphic Ventricular Tachycardia
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT).
- Trial name
- ARTEMIS (NCT07148089)
- Testing
- SGT-501
- Where
- 5 sites in United States, Canada
- Volunteers
- 18 people
- Sponsor
- Solid Biosciences Inc.
SCLC
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Explore the relationship between drug target topoisomerase I gene single nucleotide polymorphisms and Topotecan therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets'…
- Trial name
- Drug-SNP (NCT07145333)
- Testing
- Topotecan - usual, Topotecan - study
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair
CPVT1, Heart Defects, Congenital
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when…
- Conditions
- CPVT1, Heart Defects, Congenital, Heart Diseases, Ventricular Tachycardia
- Trial name
- CPVT (NCT06005428)
- Testing
- CRD-4730
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 7 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Adverse Drug Events, Adverse Drug Reactions
YouScript IMPACT Registry
This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized…
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- IMPACT (NCT02191358)
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Genelex Corporation
Prediabetes, Diabetes Type 1
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
G (guanine nucleotide binding) proteins associating with G protein-coupled receptors (GPCR) are key players in the pathogenesis of obesity and diabetes and are targets of pharmacotherapeutic inter-ventions.
- Conditions
- Prediabetes, Diabetes Type 1, Diabetes Type 2
- Trial name
- NCT02057497
- Volunteers
- healthy volunteers welcome
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Catecholaminergic Polymorphic Ventricular Tachycardia
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
This trial is conducted in patients with an inherited heart rhythm disorder called catecholaminergic polymorphic ventricular tachycardia (CPVT).
- Trial name
- NCT07263139
- Testing
- AGP100
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Agiana Pharmaceuticals